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Abstract
Background
Accurate diagnosis and subsequent treatment of latent tuberculosis infection (LTBI) is
essential for TB elimination. However, the absence of a gold standard test for diagnosing
LTBI makes assessment of the true prevalence of LTBI and the accuracy of diagnostic tests
challenging. Bayesian latent class models can be used to make inferences about disease
prevalence and the sensitivity and specificity of diagnostic tests using data on the concor-
dance between tests. We performed the largest meta-analysis to date aiming to evaluate
the performance of tuberculin skin test (TST) and interferon-gamma release assays
(IGRAs) for LTBI diagnosis in various patient populations using Bayesian latent class
modelling.
Methods
Systematic search of PubMeb, Embase and African Index Medicus was conducted without
date and language restrictions on September 11, 2017 to identify studies that compared the
performance of TST and IGRAs for LTBI diagnosis. Two IGRA methods were considered:
QuantiFERON-TB Gold In Tube (QFT-GIT) and T-SPOT.TB. Studies were included if they
reported 2x2 agreement data between TST and QFT-GIT or T-SPOT.TB. A Bayesian latent
class model was developed to estimate the sensitivity and specificity of TST and IGRAs in
various populations, including immune-competent adults, immune-compromised adults and
children. A TST cut-off value of 10 mm was used for immune-competent subjects and 5 mm
for immune-compromised individuals.
Findings
A total of 157 studies were included in the analysis. In immune-competent adults, the sensi-
tivity of TST and QFT-GIT were estimated to be 84% (95% credible interval [CrI] 82–85%)
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and 52% (50–53%), respectively. The specificity of QFT-GIT was 97% (96–97%) in non-
BCG-vaccinated and 93% (92–94%) in BCG-vaccinated immune-competent adults. The
estimated figures for TST were 100% (99–100%) and 79% (76–82%), respectively. T-
SPOT.TB has comparable specificity (97% for both tests) and better sensitivity (68% versus
52%) than QFT-GIT in immune-competent adults. In immune-compromised adults, both
TST and QFT-GIT display low sensitivity but high specificity. QFT-GIT and TST are equally
specific (98% for both tests) in non-BCG-vaccinated children; however, QFT-GIT is more
specific than TST (98% versus 82%) in BCG-vaccinated group. TST is more sensitive than
QFT-GIT (82% versus 73%) in children.
Conclusions
This study is the first to assess the utility of TST and IGRAs for LTBI diagnosis in different
population groups using all available data with Bayesian latent class modelling. Our results
challenge the current beliefs about the performance of LTBI screening tests, and have
important implications for LTBI screening policy and practice. We estimated that the perfor-
mance of IGRAs is not as reliable as previously measured in the general population. How-
ever, IGRAs are not or minimally affected by BCG and should be the preferred tests in this
setting. Adoption of IGRAs in settings where BCG is widely administered will allow for a
more accurate identification and treatment of LTBI.
Introduction
Reliable detection of latent tuberculosis infection (LTBI) is a priority as this will help direct
appropriate use of limited resources for tuberculosis (TB) control. One-third of the world’s
population have LTBI with 10% of these individuals eventually developing active TB [1]. The
risk of progression from LTBI to active TB is considerably higher in the presence of predispos-
ing factors such as immune-compromised conditions [2]. Treatment costs of TB, particularly
multi-drug-resistant infection are high [3]. Cases with pulmonary TB disease are the source of
ongoing transmission in the community.
Diagnosis of LTBI suffers from the absence of a gold standard test. The tuberculin skin test
(TST) remains the most widely used principally due to its low cost. However, it is substantially
affected by cross-reactivity with non-tuberculous mycobacterial proteins found in the Bacillus
Calmette-Gue´rin (BCG) vaccine, causing false-positive test results [4]. Interferon-gamma
release assays (IGRAs), including the commercially available assays QuantiFERON-TB Gold
In Tube (QFT-GIT; Qiagen, Hilden, Germany), and the T-SPOT.TB (Oxford Immunotec,
Oxfordshire, UK), are used as alternatives to TST in settings where higher test acquisition
costs can be supported. IGRAs are thought to be more specific than TST as they measure inter-
feron-gamma released by T-cells after stimulation with Mycobacterium tuberculosis-specific
antigens absent in BCG and most non-tuberculosis mycobacteria [5].
The diagnostic performance of IGRAs for LTBI in clinical practice has been evaluated in a
number of studies in immune-competent adults, which largely show that these tests have
higher specificity than TST [6,7]. The data on the reliability of IGRAs for the diagnosis of LTBI
in immune-compromised adults and children have not been resolved with certainty. Without
a gold standard, the true prevalence of disease and accuracy of diagnostic tests are difficult to
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measure reliably. Many studies have instead compared the performance of IGRAs against TST
by evaluating the agreement between these tests.
Bayesian latent class models can be used to make inferences about disease prevalence and
the sensitivity and specificity of diagnostic tests using data on the concordance between tests
[8–10]. This approach is based on the notion that the observed results of various imperfect
diagnostic tests for the same disease are influenced by an underlying unobserved (i.e. latent)
variable, the true disease status [8–10]. In this study, we used the Bayesian latent class model-
ling approach to evaluate the diagnostic performance of IGRAs (QFT-GIT and T-SPOT.TB)
and TST for the diagnosis of LTBI in various population groups.
Methods
Search strategy and selection criteria
A systematic literature search of PubMed, Embase and African Index Medicus databases was
conducted on September 11, 2017 to identify original studies that evaluated the concordance
between TST and QFT-GIT or T-SPOT.TB for the diagnosis of LTBI in human subjects. The
search included the following Medical Subject Headings (MeSH) terms or text key words:
(tuberculin[mesh]) OR “TST” OR “Mantoux”) and (“interferon gamma release assay” OR
“interferon gamma assay” OR “QuantiFero” OR “IGRA” OR “T-SPO” OR “TSPO” OR “Eli-
spot” OR CFP10 OR ESAT6) and (tuberculosis[mesh]). No restrictions on date, language, or
type of studies were applied. The full search strategy is described in S1 Text. Secondary search-
ing of the reference lists of relevant articles and reviews was also performed for saturation.
Titles and abstracts were screened by three authors (TD, AS, and GS) to remove articles that
were not relevant to our study. After this initial screening, full-texts of potentially relevant
studies were obtained and reviewed independently by at least two of the authors (TD, DE, AS,
and GS). Articles were included in this study if they met the following data criteria: 2x2 agree-
ment tables or sufficient information that allowed the construction of such tables between TST
and QFT-GIT or T-SPOT.TB; used a TST cut-off value of 5 mm or 10 mm; included IGRAs
that were commercial versions using a mixture of the synthetic peptides ESAT-6 and CFP-10;
and that the tests were used for the diagnosis of LTBI. This study was reported in accordance
with the PRISMA Statement [11]. The review protocol was registered with the International
prospective register of systematic reviews (PROSPERO) (CRD42017060705).
Data synthesis and analysis
Data from each eligible study were extracted by two independent reviewers. Discrepancies
between the two reviewers were resolved by consensus or by consultation with a third reviewer
(DE) if consensus could not be reached. The following variables were extracted: year of publica-
tion, country of origin, population group, BCG vaccination rate, TST cut-off value, methods of
IGRAs, age range and mean/median where available, proportion of participants on immuno-
suppressive therapy, and 2x2 test agreement data (TST+/IGRA+, TST+/IGRA-, TST-/IGRA+,
TST-/IGRA-). If separate agreement tables were available for different subgroups of patients,
these data were included separately [6]. Authors were contacted for further information where
appropriate. The QUADAS-2 checklist for the quality assessment of diagnostic accuracy studies
was used for quality assessment of the included studies [12]. A description of the QUADAS-2
items can be found in S2 Text.
The primary outcome was the diagnostic performance, i.e. sensitivity, specificity, positive
predictive value and negative predictive value, of TST, QFT-GIT and T-SPOT.TB in immune-
competent adults aged 15 years or above. For studies to be included in this primary analysis, the
prevalence of immune-compromised conditions had to be less than 5% [6]. Subgroup analyses
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investigating the diagnostic performance of TST and QFT-GIT were performed on immune-
competent children ( 14 years of age) and immune-compromised adults. Subgroup analyses
on these population groups were not performed with T-SPOT.TB due to insufficient data. In
accordance with international guidelines [13–15] and real-life clinical practice, we used a TST
cut-off value of 10 mm for immune-competent subjects and 5 mm for immune-compromised
individuals. We allowed for factors that could potentially lead to variability of diagnostic test
performance between studies including BCG vaccination rate and immune status.
Bayesian latent class model
We developed a Bayesian latent class model to describe the observed 2x2 data to estimate the
true prevalence (π) of LTBI in the population, and the sensitivity (S1, S2) and specificity (C1,
C2) of TST (test 1, T1) and IGRA (test 2, T2). Let D be the unknown (latent) true disease status,
the prevalence, sensitivity and specificity can be formally expressed as follows:
p ¼ PðDþÞ; S1 ¼ PðT1 þ jDþÞ; S2 ¼ PðT2 þ jDþÞ;C1 ¼ PðT1   jD  Þ; and C2
¼ PðT2   jD  Þ: ð1Þ
The observed data follow a multinomial distribution where each probability of the four combi-
nations of the results of the two tests can be expressed in terms of π, S1, S2, C1 and C2 as follows:
PðT1þ; T2þÞ ¼ pS1S2 þ ð1   pÞð1   C1Þð1   C2Þ;
PðT1þ; T2  Þ ¼ pS1ð1   S2Þ þ ð1   pÞð1   C1ÞC2;
PðT1  ; T2þÞ ¼ pð1   S1ÞS2 þ ð1   pÞC1ð1   C2Þ;
PðT1  ; T2  Þ ¼ pð1   S1Þð1   S2Þ þ ð1   pÞC1C2:
ð2Þ
In the latent class model in Eq 2, π, S1, S2, C1 and C2 were the unknown model parameters to
be estimated. A Bayesian approach was used to make inferences about these unknown parame-
ters. This approach combines the observed data, i.e. 2x2 table, and prior knowledge about the
parameters formally expressed as a prior probability distribution, to obtain a posterior probabil-
ity distribution of the unknown parameters. We assumed a beta(α,β) distribution for the priors
of the sensitivity and specificity. Beta distribution was chosen because its region of positive den-
sity ranges from 0 to 1, matching the range of these parameters [8]. It also has the advantage of
being flexible, allowing a wide variety of the shapes of the distribution to be determined by
selecting different choices of α and β [8]. The α and β parameters of the beta distributions of the
sensitivity and specificity of T1 and T2 were determined by equating the midpoint of the range
reported in the literature to the mean (μ) of the beta distribution, and equating one quarter of
the range to the standard deviation (δ) of the beta distribution [10]. The mean, standard devia-
tion and the parameters of a beta distribution were given by the following equations:
m ¼
a
aþ b
;
d ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ab
ðaþ bÞ
2
ðaþ bþ 1Þ
s
;
a ¼  
mðd
2
þ m2   mÞ
d
2
;
b ¼
ðm   1Þðd
2
þ m2   mÞ
d
2
:
ð3Þ
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For TST (T1), the sensitivity reported in the literature ranged from 57% to 95% [16,17],
while the specificity ranged from 55% to 100% [18,19]. Using Eq 3, these corresponded to beta
(14.6, 4.6) and beta(9.9, 2.88) for S1 and C1, respectively. The sensitivity of IGRAs reported in
the literature ranged from 55% to 93% [18,20], and their specificity ranged from 89% to 100%
[21,22]. These were converted into beta(15.04, 5.28) and beta(64, 3.7) for S2 and C2, respec-
tively. A uniform(0, 0.9) was used for the priors of LTBI prevalence (π), knowing that the high-
est prevalence rate reported in the literature was 90% [23]. This distribution assigns equal
weights to all possible values from 0 to 0.9 to allow LTBI prevalence to vary freely within this
range among studies (i.e. populations). A separate estimate of prevalence for each population
was performed.
We also estimated the effect of BCG on the specificity of the tests as follows:
C1i ¼ pEBCG þ ð1   pÞC1; ð4Þ
where C1i is the specificity of a test in the current (ith) population, p is the proportion of indi-
viduals in that population who is vaccinated, and EBCG is the effect of BCG on the specificity of
the test in that population.
Positive predictive value (PPV) and negative predictive value (NPV) were also estimated
using the following formulae. S3 Text describes how these formulae were derived.
PPV ¼ P Dþ jTþð Þ ¼
Sp
Spþ ð1   CÞð1   pÞ
;
NPV ¼ P D   jT ð Þ ¼
Cð1   pÞ
ð1   SÞpþ Cð1   pÞ
:
ð5Þ
Bayesian inferences with the Gibbs sampler algorithm was used to estimate the model
parameters. For each parameter, three Markov chains were constructed, each chain with dif-
ferent initial values. Convergence of the Markov chains was assessed by visual inspection of
the density plots of parameter estimates and by examining the Gelman-Rubin statistics [24]. A
Gelman-Rubin value of less than 1.1 was considered convergence [24]. We ran each chain
with 70,000 iterations and a burn-in period of 10,000. For each parameter, median estimates
and their 95% credible interval (CrI) were reported. The log-odds ratio check (LORC) method
was used for assessment of conditional independence between the two test observations [25].
Briefly, the LORC investigates how well a model describes a particular dataset by comparing
the empirical pairwise log-odds ratios with the pairwise predicted log-odds ratios [25]. The dif-
ference between the observed and expected log-odds ratios is expressed by a z-score. A z-score
within the ±1.96 range indicates that the assumption of conditional independence is valid [25].
All analyses were performed in WinBUGS (version 1.4, Imperial College & Medical Research
Council, UK). As this study used data from published literature, ethics approval was not
required.
Results
A total of 2,195 articles were identified from the initial searches. After assessment of titles and
abstracts, 480 articles were assessed as potentially relevant and their full-texts were reviewed.
Of these, 157 articles met the a priori inclusion criteria [26–182]. These studies comprised 170
agreement tables. The earliest and latest years of publication were 2006 and 2017, respectively.
Of the included studies, four were published in languages other than English (one Polish, three
Spanish); however, the full-texts of these studies were already translated into English by the
journal. Fig 1 outlines how the final sample size was reached.
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The characteristics of the included studies are shown in Table 1. Eighty seven percent (137/
157) of the included studies reported rates of BCG vaccination. The majority (132/157, 84%)
of the studies were conducted in adults (15 years of age). Twenty five percent (39/157) of the
studies were conducted in patients selected because of altered immunity due to the presence of
HIV/AIDS, solid organ transplantation, stem cell transplantation, immune-mediated inflam-
matory diseases, end-stage kidney disease or malignancy. QFT-GIT was the most common
Fig 1. Flowchart of study selection. TB, tuberculosis; TST, tuberculin skin test.
https://doi.org/10.1371/journal.pone.0188631.g001
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Table 1. Characteristics of the included studies.
Reference Country Population Age range
(years)
BCG rate
(%)
2x2 data*
Immune-competent,
IGRA = QFT-GIT
Diel et al. (2006) [26] Germany Contacts Any age 50.8 25, 39, 6, 239
Nakaoka et al. (2006) [27] Nigeria Contacts 1–14 90 40, 14, 8, 93
Tsiouris et al. (2006) [28] South Africa Students 5–15 72.3 51, 29, 10, 94
Adetifa et al. (2007) [29] Gambia Contacts 15 43 69, 16, 33, 57
Arend et al. (2007) [30] Netherlands Unvaccinated 17 0 74, 186, 7, 518
Dogra et al. (2007) [31] India Contacts 1–12 82 8, 2, 3, 92
Franken et al. (2007) [32] Netherlands Military personnel 18 12.6 19, 120, 2, 535
Silverman et al. (2007) [33] Canada Contacts 18 100 3, 10, 0, 9
Chun et al. (2008) [34] Korea Contacts 13 100 9, 12, 1, 47
Healthy controls 14 100 1, 41, 0, 23
Mirtskhulava et al. (2008) [35] Georgia HCW 18–74 92 133, 44, 26, 62
Petrucci et al. (2008) [36] Nepal Contacts 15 84.9 65, 9, 5, 58
Brazil Contacts 15 84.9 33, 2, 12, 63
Baker et al. (2009) [37] USA Refugees 1–81 NR 85, 23, 20, 67
Bianchi et al. (2009) [38] Italy Contacts, Immigrants 16 51.5 33, 21, 27, 253
Fox et al. (2009) [39] Israel HCW 18 34 9, 22, 8, 52
Herrmann et al. (2009) [40] France HCW 24–53 100 4, 9, 2, 4
Kik et al. (2009) [41] Netherlands Contacts 16 NR 142, 97, 10, 33
Kim et al. (2009) [42] Korea Immune-competent 19–98 100 17, 8, 7, 53
Lien et al. (2009) [43] Vietnam HCW 20–58 32 114, 49, 21, 71
Lighter et al. (2009) [44] USA Mixed 18 36 27, 88, 4, 85
Machado et al. (2009) [45] Brazil Contacts Any age 76 100, 44, 17, 94
Ringshausen et al. (2009) [46] Germany HCW 20–62 51 7, 22, 6, 108
Saracino et al. (2009) [47] Italy Immigrants Any age NR 49, 23, 58, 149
Torres Costa et al. (2009) [48] Portugal HCW 16 100 371, 532, 26, 289
Tripodi et al. (2009) [49] France HCW 20–60 100 23, 74, 5, 46
Vinton et al. (2009) [50] Australia HCW 20–66 78 16, 98, 5, 222
Zhao et al. (2009) [51] USA HCW 18 NR 10, 10, 0, 20
Adetifa et al. (2010) [52] Gambia Contacts 0.5–14 59 43, 14, 29, 127
Costa et al. (2010) [53] Portugal HCW 16 100 525, 792, 33, 332
Grare et al. (2010) [54] France Contacts 18 45.4 5, 10, 0, 22
Huang et al. (2010) [55] Taiwan Contacts Any age 89 12, 24, 3, 39
Jong Lee et al. (2010) [56] Korea HCW 22–53 100 10, 21, 9, 42
Katsenos et al. (2010) [57] Greece Army recruits 18–35 100 11, 85, 2, 31
Lee et al. (2010) [58] Korea Contacts 16–70 67.2 97, 29, 11, 48
Torres Costa et al. (2010) [59] Portugal HCW 18 63.7 525, 792, 33, 332
Thomas et al. (2010) [60] Bangladesh Mixed 11–15.3 79 72, 16, 35, 105
Tsolia et al. (2010) [61] Greece Mixed 15 NR 58, 70, 4, 16
Caglayan et al. (2011) [62] Turkey HCW Any age 87 33, 32, 1, 12
Diel et al. (2011) [63] Germany Contacts 1–62 52 138, 104, 60, 652
Kasambira et al. (2011) [64] South Africa Contacts 16 95 48, 7, 27, 154
Kus et al. (2011) [65] Poland Healthy 18 100 85, 140, 41, 186
Legesse et al. (2011) [66] Ethiopia General 18–70 17.4 151, 16, 76, 28
Moon et al. (2011) [67] Korea HCW 22–67 100 18, 34, 14, 90
Moyo et al. (2011) [68] South Africa Contacts 3 100 57, 13, 11, 295
(Continued )
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Table 1. (Continued)
Reference Country Population Age range
(years)
BCG rate
(%)
2x2 data*
Pavic et al. (2011) [69] Croatia Contacts 0–5 100 14, 11, 4, 112
Rafiza et al. (2011) [70] Malaysia HCW 19–56 99.7 11, 45, 2, 37
Shanaube et al. (2011) [71] Zambia, South Africa Contacts 15 NR 577, 148, 570, 508
Talebi-Taher et al. (2011) [72] Iran HCW 23–59 100 14, 91, 3, 92
Torres Costa et al. (2011) [73] Portugal HCW 18 68.2 850, 1252, 103, 679
Torres Costa et al. (2011) [74] Portugal HCW 16 98.6 153, 344, 8, 67
Weinfurter et al. (2011) [75] USA Mixed 13 36 167, 155, 64, 1267
Yassin et al. (2011) [76] Ethiopia Contacts 15 52 87, 39, 24, 59
Healthy controls 15 52 6, 10, 12, 86
Bergot et al. (2012) [77] France Contacts 12–97 20.4 28, 50, 7, 62
Di Renzi et al. (2012) [78] Italy Staff of homeless shelter 25–71 6.5 22, 0, 2, 27
Healthy controls 18 66 16, 12, 3, 10
He et al. (2012) [79] Mongolia HCW 18–72 26 350, 89, 288, 190
Jeong et al. (2012) [80] Korea X-ray healed TB 36–88 42.6 79, 10, 48, 26
Jo et al. (2012) [81] Korea Contacts Any age 78.2 34, 14, 20, 33
Jung da et al. (2012) [82] Korea Medical students 18 86.3 6, 17, 2, 128
Larcher et al. (2012) [83] Italy HCW 19–64 38 57, 103, 24, 365
Onur et al. (2012) [84] Turkey Outpatient paediatric
clinic
14 87.6 33, 18, 4, 36
Pattnaik et al. (2012) [85] India Contacts 15 40.7 64, 24, 1, 11
Zwerling et al. (2012) [86] Canada HCW 18 36.1 7, 15, 17, 348
Jo et al. (2013) [87] Korea HCW 20 81 54, 127, 31, 281
Serrano-Escobedo et al. (2013) [88] Mexico Contacts 18 87 31, 11, 20, 61
Whitaker et al. (2013) [89] Georgia HCW 18 89 68, 38, 9, 39
Zwerling et al. (2013) [90] Canada HCW 18 61.6 3, 10, 10, 234
Alvarez et al. (2014) [91] Canada High risk groups Any age 73 46, 40, 4, 166
Charisis et al. (2014) [92] Greece HCW 20 68 30, 179, 2, 32
de Souza et al. (2014) [93] Brazil HCW 18 86.4 114, 138, 58, 322
Erkens et al. (2014) [94] Netherlands Mixed Any age 40 870, 1777, 66, 639
Garazzino et al. (2014) [95] Italy General 2 NR 0, 10, 9, 463
Garcell et al. (2014) [96] Qatar HCW 18 NR 10, 9, 1, 182
Goodwin et al. (2014) [97] USA Army recruits 17–36 1 1, 13, 5, 2062
Mathad et al. (2014) [98] India Pregnant women 18 NR 46, 12, 79, 206
Ribeiro-Rodrigues et al. (2014) [99] Brazil Contacts 0.5–87 77.3 159, 36, 14, 100
Sauzullo et al. (2014) [100] Italy HCW 25–60 3.1 34, 29, 0, 126
Song et al. (2014) [101] Korea Contacts 11–19 61 231, 430, 86, 2219
Adams et al. (2015) [102] South Africa HCW 18 92 293, 112, 24, 53
El-Sokkary et al. (2015) [103] Egypt HCW 18 92.4 26, 52, 12, 42
Gao et al. (2015) [104] China Mixed 5 50.6 2933, 2945, 1013,
13587
Goebel et al. (2015) [105] Australia Contacts Any age 84 160, 194, 18, 91
He et al. (2015) [106] Mongolia HCW 19–77 36.4 122, 45, 276, 422
Howley et al. (2015) [107] Vietnam, Philippines,
Mexico
Migrants to USA 2–14 100 111, 553, 31, 1812
Jones-Lopez et al. (2015) [108] Uganda Contacts 10 2 182, 19, 15, 36
Lucet et al. (2015) [109] France HCW 18 97.4 95, 348, 18, 343
Ferrarini et al. (2016) [110] Brazil Contacts 15 98.3 31, 3, 3, 4
(Continued )
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Table 1. (Continued)
Reference Country Population Age range
(years)
BCG rate
(%)
2x2 data*
Al Hajoj et al. (2016) [111] Saudi Arabia HCW 18 90.6 227, 275, 172, 921
Biraro et al. (2016) [112] Uganda Contacts 0–30 78 62, 7, 92, 76
Bozkanat et al. (2016) [113] Turkey HCW 18 94.1 7, 21, 0, 6
Grare et al. (2010) [114] France Children NR 41 5, 7, 0, 32
Lowenthal et al. (2016) [115] USA Immigrants 2–14 NR 142, 523, 3, 48
Marco Mourino et al. (2011) [116] Spain Prisoners 19–66 17 27, 13, 10, 99
Marquez et al. (2016) [117] Uganda Children 0–5 94 10, 114, 10, 343
Miramontes et al. (2015) [118] USA General 6 NR 127, 158, 176, 5603
Mostafavi et al. (2016) [119] Iran HCW 20 86 13, 26, 29, 176
Nienhaus et al. (2011) [120] Germany, Portugal, France HCW 18 NR 409, 654, 41, 523
Oren et al. (2016) [121] USA Migrant farmers 48 74 16, 8, 12, 32
Pavic et al. (2015) [122] Croatia Contacts <5 98.8 18, 13, 8, 132
Reechaipichitkul et al. (2015) [123] Thailand Contacts NR 86 15, 24, 5, 56
Rose et al. (2015) [124] Canada Contacts 0–17 42 27, 16, 4, 47
Salinas et al. (2015) [125] Spain Immigrants 12–18 26.75 140, 103, 2, 34
Sharma et al. (2017) [126] India Contacts 1–65 76 540, 187, 377, 394
Yoo et al. (2016) [127] Korea Contacts NR 84 92, 71, 40, 241
Anibarro et al. (2011) [128] Spain Contacts 18 36 68, 14, 5, 50
Diel et al. (2008) [129] Germany Contacts 1–56 46 62, 181, 4, 354
Ferreira et al. (2015) [130] Brazil Contacts 18 86.7 19, 5, 9, 27
Nienhaus et al. (2008) [131] Germany HCW 18–67 37.5 15, 48, 10, 188
Immune-competent,
IGRA = T-SPOT.TB
Porsa et al. (2006) [132] USA Prisoners 18 NR 9, 28, 13, 359
Arend et al. (2007) [30] Netherlands Unvaccinated 17 0 103, 151, 39, 466
Rangaka et al. (2007) [133] South Africa Mixed Any age 71 40, 21, 5, 8
Bienek & Chang (2009) [134] USA Unvaccinated 18–41 3 2, 0, 6, 318
Janssens et al. (2008) [135] Switzerland Contacts 16–83 80.6 78, 65, 37, 100
Leung et al. (2008) [136] Hong Kong Silicosis 18 1.5 72, 20, 14, 28
Soysal et al. (2008) [137] Turkey Healthy Any age 83 7, 18, 0, 21
Girardi et al. (2009) [138] Italy HCW 18 37.4 37, 24, 5, 49
Hansted et al. (2009) [139] Lithuania Contacts 10–17 100 7, 20, 1, 17
Low risk 10–17 100 3, 31, 2, 16
Kik et al. (2009) [41] Netherlands Contacts 16 NR 154, 85, 14, 29
Adetifa et al. (2010) [52] Gambia Contacts 0.5–14 59 43, 14, 27, 129
Leung et al. (2010) [140] Hong Kong Silicosis 18 3.5 168, 35, 36, 69
Borkowska et al. (2011) [141] Poland HCW 27–73 100 7, 4, 0, 6
Zhao et al. (2011) [142] China Students 17–24 0 11, 26, 16, 103
Larcher et al. (2012) [83] Italy HCW 19–64 38 24, 51, 35, 282
Nkurunungi et al. (2012) [143] Uganda Healthy 5 100 17, 6, 51, 218
Adams et al. (2015) [102] South Africa HCW 18 92 249, 126, 20, 55
Leung et al. (2015) [144] Hong Kong Contacts 5–64 66 254, 228, 89, 478
Spicer et al. (2015) [145] USA Mixed 0.3–16 72.5 5, 18, 0, 71
Non-TB diseases 25–63 100 0, 3, 1, 26
Immune-compromised,
IGRA = QFT-GIT
(Continued )
Diagnosis of latent tuberculosis infection
PLOS ONE | https://doi.org/10.1371/journal.pone.0188631 November 28, 2017 9 / 26
IGRA, used in 87% (137/157) of the included studies. T-SPOT.TB was used in 15/157 studies;
all of which included only immune-competent adults. The remaining studies (5/150) used
both methods.
Table 1. (Continued)
Reference Country Population Age range
(years)
BCG rate
(%)
2x2 data*
Mendez-Echevarria et al. (2011)
[146]
Spain IMID 18 5.6 4, 3, 5, 37
Moon et al. (2011) [67] Korea Stem cell transplant 35–55 82 9, 24, 31, 146
Takahashi et al. (2007) [147] USA HIV 22–79 7.4 2, 5, 7, 259
Aichelburg et al. (2014) [148] Austria HIV 18 NR 24, 3, 13, 195
Balcells et al. (2008) [149] Chile HIV 21–71 88 9, 2, 8, 90
Bourgarit et al. (2015) [150] France HIV 18 60.6 20, 42, 14, 316
Casas et al. (2011) [151] Spain IMID NR 26 43, 19, 13, 210
Casas et al. (2011) [152] Spain ESRD NR 31.6 34, 10, 9, 42
Chkhartishvili et al. (2013) [153] Georgia HIV 18 94 25, 16, 44, 148
Gogus et al. (2010) [154] Turkey IMID 20–70 100 8, 17, 1, 12
Hanta et al. (2012) [155] Turkey IMID 18 92 24, 32, 10, 24
Hsia et al. (2012) [156] Worldwide IMID All age 34.2 59, 150, 101, 1931
James et al. (2014) [157] India HIV 18 100 10, 16, 4, 18
Jones et al. (2007) [158] USA HIV All age 2 5, 8, 6, 172
Karadag et al. (2010) [159] Turkey IMID All age 100 19, 34, 2, 39
Khawcharoenporn et al. (2015)
[160]
Thailand HIV 17–65 73 8, 16, 12, 114
Kim et al. (2014) [161] Korea IMID All age 70.7 56, 77, 12, 269
Kim et al. (2013) [162] Korea IMID All age NR 102, 133, 81, 408
Kim et al. (2015) [163] Korea IMID All age NR 52, 67, 26, 271
Latorre et al. (2014) [164] Spain IMID 18 NR 1, 6, 11, 81
Manuel et al. (2007) [165] Canada Liver transplant 18 82 18, 9, 16, 98
Matulis et al. (2008) [166] Switzerland IMID 18 83 10, 34, 5, 60
Minguez et al. (2012) [167] Spain IMID 18 5.6 4, 3, 5, 37
Moon et al. (2013) [168] Korea Stem cell transplant 35–55 82 9, 24, 31, 146
Papay et al. (2011) [169] Austria IMID NR 100 6, 20, 9, 157
Ramos et al. (2013) [170] Spain IMID 16–82 19 13, 30, 2, 107
Ramos et al. (2012) [171] Spain HIV 15–85 15.8 21, 25, 8, 40
Sauzullo et al. (2010) [172] Italy IMID 18–80 8.7 27, 26, 5, 11
Talati et al. (2009) [173] USA HIV 22–79 7.4 2, 5, 7, 259
Vassilopoulos et al. (2011) [174] Greece IMID 18 76 17, 41, 15, 82
Hoffmann et al. (2010) [175] Switzerland Haemodialysis 30–87 18 5, 2, 4, 21
Mariette et al. (2012) [176] France IMID All age 65.7 24, 114, 15, 239
Ponce de Leon et al. (2008) [177] Peru IMID All age 80.2 21, 6, 24, 50
Scrivo et al. (2012) [178] Italy IMID 18–80 5.8 2, 11, 3, 82
Cho et al. (2016) [179] Korea IMID NR 77.9 19, 16, 19, 148
Kurti et al. (2015) [180] Hungary IMID 18–30 100 7, 28, 5, 126
Kussen et al. (2016) [181] Brazil HIV 18 78 9, 4, 12, 115
Palomar et al. (2011) [182] Spain Haemodialysis NR 42.6 7, 9, 3, 26
* TST+/IGRA+, TST+/IGRA-, TST-/IGRA+, TST-/IGRA-.
ESRD, end stage renal disease; IGRA, interferon gamma release assay; IMID, immune-mediated inflammatory disease; HCW, healthcare worker; NR, not
reported; QFT-GIT, QuantiFERON-TB Gold In Tube; TB, tuberculosis.
https://doi.org/10.1371/journal.pone.0188631.t001
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The results of the quality assessment of the included studies are summarised in Fig 2 and
presented for each individual study in S1 Table. Many studies did not report all the informa-
tion that could be used to fully assess the quality of the study. For the “patient selection”
domain, most studies (154/157, 98%) were deemed to have low risk of bias (Fig 2). The
remaining 2% were considered to have high risk of bias because these studies used a case-con-
trol study design in which the status of LTBI were known prior to the test. For the “diagnostic
test domains”, risk of bias could not be assessed for the majority of studies because it was
unknown whether the results of one test were interpreted without knowledge of the results of
the other test (Fig 2). Nine percent (14/157) of the studies were deemed to have high risk of
bias for the “patient flow and timing of tests domain” because there were participants excluded
from the analysis without explanation given (Fig 2). There was unclear risk of bias for this
domain for 50% (78/157) of the studies because the interval between the two tests was not
reported (Fig 2).
Table 2 shows the estimated sensitivity and specificity of TST, QFT-GIT and T-SPOT.TB in
different populations. In immune-competent non-BCG-vaccinated adults, TST has better sen-
sitivity (84% versus 52%) and slightly better specificity (100% versus 97%) than QFT-GIT.
BCG vaccination significantly reduces the specificity of TST, from 100% in non-vaccinated
subjects to 79% in BCG-vaccinated subjects; whereas the effect of BCG on the specificity of
QFT-GIT is modest (Table 2). T-SPOT.TB has comparable specificity (97% for both tests) and
better sensitivity (68% versus 52%) than QFT-GIT in immune-competent adults. In immune-
compromised adults, QFT-GIT is less sensitive than TST (46% versus 71%) whereas the speci-
ficity of both tests is comparable (97% versus 99% in non-BCG-vaccinated adults, 93% for
both tests in BCG-vaccinated adults) (Table 2). QFT-GIT and TST have comparable specificity
in non-BCG-vaccinated children; however the former is less sensitive than the latter (Table 2).
The specificity of QFT-GIT in BCG-vaccinated children is not affected by BCG and is substan-
tially better than that of TST (98% versus 82%) (Table 2).
Fig 2. Summary of quality assessment results. Risk of Bias of each QUADAS-2 domain presented as percentages across the 157 included studies. IGRA;
interferon-gamma release assay; TST, tuberculin skin test.
https://doi.org/10.1371/journal.pone.0188631.g002
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The mean prevalence of LTBI among the populations where the studies were performed
was estimated to be 49% (standard deviation ± 27%). The relationship between prevalence and
predictive values is shown in Fig 3. In a high-prevalence setting (prevalence > 50%), QFT-GIT
Table 2. Estimated sensitivity and specificity of TST and IGRAs in different population groups.
Parameter Diagnostic test Immune-competent adults*
median (95% CrI)
Immune-compromised adults†
median (95% CrI)
Immune-competent children*
median (95% CrI)
Sensitivity (%) QFT-GIT 52 (50–53) 46 (43–49) 73 (70–76)
TST 84 (82–85) 71 (66–75) 82 (79–84)
Specificity (%) QFT-GIT (non-BCG) 97 (96–97) 97 (96–98) 98 (97–99)
QFT-GIT (BCG) 93 (92–94) 93 (92–95) 98 (97–99)
TST
(non-BCG)
100 (99–100) 99 (97–100) 98 (96–99)
TST (BCG) 79 (76–82) 93 (91–96) 82 (81–83)
*TST cut-off value = 10 mm
†TST cut-off value = 5 mm
BCG, Bacillus Calmette-Gue´rin; CrI, credible interval; QFT-GIT, QuantiFERON-TB Gold In Tube; TST, tuberculin skin test.
https://doi.org/10.1371/journal.pone.0188631.t002
Fig 3. Relationship between prevalence and predictive value in immune-competent adults. BCG, Bacillus
Calmette-Gue´rin; LTBI, latent tuberculosis infection; NPV, negative predictive value; PPV, positive predictive
value; QFT-GIT, QuantiFERON-TB Gold In Tube; TB, tuberculosis; TST, tuberculin skin test.
https://doi.org/10.1371/journal.pone.0188631.g003
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has a PPV of at least 88% and a NPV value of at most 69%. The PPV of TST is around 100% in
non-BCG-vaccinated and at least 73% in BCG-vaccinated subjects. The NPV of TST was esti-
mated to be 71% and 61% in these populations, respectively.
Discussion
Accurate identification and subsequent treatment of LTBI is essential to TB control and elimi-
nation. The lack of a gold standard for diagnosing LTBI means that the true prevalence of the
disease is unknown, and the estimations of the sensitivity and specificity of diagnostic tests
are unreliable. This study represents the most comprehensive Bayesian latent class analysis
of published data on the performance of TST and IGRAs for the diagnosis of LTBI. We have
confirmed that IGRAs have high specificity but that these tests have considerably lower sensi-
tivity than TST in immune-competent populations than had previously been demonstrated
[6,7,183]. A meta-analysis by Pai et al.[7] estimated the pooled sensitivity of QFT and TST to
be 70% and 77%, respectively; the specificity of QFT to be 96–99%; and the specificity of TST
in non-BCG-vaccinated and BCG-vaccinated populations to be 97% and 59%, respectively.
Our estimate of the sensitivity of QFT-GIT is lower than that of Pai et al. [7]; however it should
be noted that the sensitivity of QFT in Pai et al. [7] was estimated in patients with active TB as
a surrogate for LTBI. It is plausible that the cellular immune response, which is the measure of
QFT, is different between LTBI and active TB disease, being higher with the latter [5]. Using a
similar latent class modelling approach, Sadatsafavi et al. [6] estimated the sensitivity and spec-
ificity of QFT in immune-competent adults to be 64.2% and 99.6%, respectively. However,
methodological differences make comparison between our results and those of Sadatsafavi
et al. [6] challenging. Sadatsafavi et al. [6], conducted in 2008, is nearly a decade old and only
included a very limited number (nineteen) of studies. Since then, a great amount of new stud-
ies that compared the diagnostic performance of IGRAs and TST in this setting have been
published. Indeed, our search has found that since the study of Sadatsafavi et al. [6] was con-
ducted, there have been 132 new studies that are included in our analysis. Sadatsafavi et al. [6]
combined all versions of QFT in their analysis, assuming no difference between these tests;
whereas our study included only the latest QFT-GIT version, which replaced the discontinued
older QFT versions. In addition, Sadatsafavi et al. [6] only included immune-competent adults;
whereas we included not only immune-competent adults but also children and immune-com-
promised individuals. The study of Sadatsafavi et al. [6] is limited to a single database and to
studies in English language only. Single database and English-only language restrictions are
likely to result in an incomplete coverage of the literature and biased estimates.
Conventional meta-analysis of diagnostic tests simply entails pooling of data to provide
pooled estimates of test sensitivity and specificity. Simple pooling of data may cause serious
bias due to confounding of disease prevalence in the contributing studies [184]. Our latent
class modelling approach accounts for the imperfect nature of the tests; and allows us to esti-
mate not only diagnostic parameters (i.e. sensitivity, specificity, predictive values), but also dis-
ease prevalence. Unlike conventional meta-analysis, Bayesian latent class modelling
incorporates prior information on sensitivity, specificity and disease prevalence, improving
the precision of model estimates for these parameters. It also allows for the quantification of
the effect of BCG on the performance of the tests, which otherwise is impossible to measure in
conventional epidemiological studies and meta-analysis. Before our study, there had been no
formal quantification of the effect of BCG on the specificity of IGRAs; even though it is gener-
ally thought that such effect, if any, is modest based on the biological mechanism of the tests,
rather than on empirical data [185]. Our study is the first to quantify the effect of BCG on the
specificity of IGRAs. We have found that such effect is minimal, confirming this hypothesis.
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We have also been able to quantify the decrement in specificity of TST in BCG-vaccinated sub-
jects. To date, studies that investigated the impact of BCG on TST have only reported such
effect as relative risk or odds ratio of having positive TST results between subjects with and
without BCG [22,23,167]. We have found that BCG negatively affects the performance of TST,
reducing the specificity of the test by 21% in the general population. In contrast, QFT-GIT has
reasonable sensitivity and superior specificity in BCG-vaccinated subjects, supporting the rec-
ommendation that QFT-GIT should be the preferred diagnostic test of LTBI in this setting
[177,178]. Of note, the effect of BCG on the specificity of the tests was inferred in our model
based on the rates of BCG vaccination. We did not take into account other factors that are
known to potentially affect the diagnostic performance of TST including age at vaccination
and time since vaccination because of the lack of data [179]. An important assumption under-
lying Bayesian latent class models is the assumption of conditional independence between the
two test observations [25]. Using the LORC method, we estimated the z-score to be 0.8, falling
within the ± 1.96 range, indicating no violation of the conditional independence assumption.
To explore the potential effects that studies deemed to be of high risk of bias may have on the
results, we performed an analysis in which these studies were excluded. We found that our
results were robust to the inclusion (or exclusion) of these studies (S2 Table).
Immune-compromised patients have an increased risk of LTBI reactivation [5]. Screening
for LTBI is therefore required prior to commencement of immunosuppressive therapies [5].
To date, data on the performance of diagnostic tests for LTBI in immune-compromised sub-
jects are limited and the few published studies evaluating the performance of TST and
QFT-GIT show conflicting results [5,186]. We have found that both tests are specific but have
suboptimal sensitivity in immune-compromised patients. We believe that more data on the
performance of TST and QFT-GIT in this population group are required.
The limitations of our study must be considered. Our results are derived from studies
where the estimates of LTBI prevalence vary widely. This is due to the heterogeneity in study
settings, populations and methodology of the included studies. Bayesian analysis requires
prior information on model parameters. One criticism of Bayesian latent class models is that
they may be sensitive to the choice of prior information. This may particularly be the case
when there are limited observed data. When the number of observed data are large, as in our
study, these begin to dominate any prior information. We believe that we have used the most
informative priors obtained from the literature. Furthermore, we performed sensitivity analy-
sis and found that our results are not sensitive to choice of prior (S3 Table).
In conclusion, our study represents the most comprehensive Bayesian latent class analysis
of the diagnostic accuracy of TST and IGRAs derived from all published agreement data. Our
results challenge the current beliefs about the performance of LTBI screening tests and provide
important information to guide choice of tests for LTBI screening that will enhance the millen-
nium goals for elimination of TB. Our findings show that IGRAs may be inferior to TST for
diagnosing LBTI in non-BCG-vaccinated populations. For BCG-vaccinated individuals,
IGRAs appear to be a more favourable choice. IGRAs will therefore allow physicians and TB
controllers to better understand the background prevalence of LTBI for targeted preventive
therapy in settings where BCG vaccination is widely administered. QFT-GIT and TST have
suboptimal sensitivity in immune-compromised patients and results should be interpreted
with caution. A combination of both tests could potentially overcome the problems of false-
positives in this setting. Considerations regarding cost-effectiveness, logistics, availability for
clinicians and patient acceptability should be taken into account to decide which test to use for
the diagnosis of LTBI.
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